BUSINESS WIRE: Board of Directors to Evaluate Requ...

BUSINESS WIRE: Board of Directors to Evaluate Request for Exclusive Due
Diligence for the

Purpose of Launching a Possible Public Offer on Sorin S.p.A.



MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS
BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
------------------------------------------------------------------------



MILAN --(BUSINESS WIRE)--22.03.2010--

The Company (MIL:SRN) has announced that it has today received a letter
requesting permission to conduct, on an exclusive basis, a due diligence on
the Company, under appropriate confidentiality measures on behalf of a
consortium composed of Ares Life Sciences AG, Essex Woodlands Health
Ventures UK Ltd, Intesa SanPaolo S.p.A. and Alpha Private Equity Funds,
(‘Consortium’).

The Consortium requests the conduct of due diligence in order to evaluate a
possible public, voluntary tender offer for the entire share capital of the
Company, on the basis of a preliminary valuation for each share of Sorin
S.p.A. of between Euro 1.40 and Euro 1.55.

The Consortium also discloses that discussions are underway with Equinox
Two S.c.A. and Mittel S.p.A., on an exclusive basis, to evaluate their
possible co-investment alongside the Consortium, as well as their
acceptance of a possible public offer made on the Company. The Consortium
also indicates that it has opened negotiations to obtain financing
necessary for the transaction.

The Board of Directors is expected to meet on Thursday March 25^th, 2010 to
examine the request from the Consortium to conduct exclusive due diligence
on the Company.

About Sorin Group

Sorin Group (www.sorin.com) is a global company and a leader in the
treatment of cardiovascular diseases. The company develops, manufactures
and markets medical technologies and innovative therapies for cardiac
surgery and for the treatment of cardiac rhythm disorders.

With 3,500 employees worldwide, the Group focuses on three major
therapeutic areas that include: cardiopulmonary bypass (extracorporeal
circulation and autotransfusion systems), cardiac rhythm management, and
heart valve repair and replacement. Every year, over 1 million patients are
treated with the devices of Sorin Group in more than 80 countries.

For more information, please visit: www.sorin.com.

[CT]

Kontakt: Martine Konorski Director, Corporate Communications Sorin Group
Tel: +33 (0)1 46 01 33 78 Mobile: +33 (0)6 76 12 67 73/+3902438114218
e-mail: martine.konorski@sorin.com or Carla Vidra Investor Relations Sorin
Group Tel: +39 02 69969716 e-mail: carla.vidra@sorin.com or Press Office
Image Building Simona Raffaelli Tel. + 39 02 89011300 e-mail:
sorin@imagebuilding.it

Pressekontakt:
BUSINESS WIRE
A Berkshire Hathaway Company
Sandweg 94 F
D-60316 Frankfurt a. M.
t. +49 (0)69-91 50 66-0
f. +49 (0)69-91 50 66-50
e. germany@businesswire.com
w. www.businesswire.de oder www.businesswire.com



vwd Vereinigte Wirtschaftsdienste AG
Tilsiter Straße 1
60487 Frankfurt am Main
Telefon: +49 69 50701-0
Telefax: +49 69 50701-126
E-Mail: info@vwd.com
www.vwd.comPermalink: http://www.ddpdirect.de/business_wire_board_of_directors_to_evaluate_request_for_exclusive_due_diligence_for_the_56093.html (Dies ist eine über ddp direct verbreitete Pressemitteilung. Für denInhalt ist ausschließlich das herausgebende Unternehmen verantwortlich.) ddp direct - mehr Medien